Merck achieved robust third-quarter growth in 2024, with organic sales up 3.8% and EBITDA pre rising 16.9%
Merck, a leading science and technology company, accelerated its growth in the third quarter of 2024. All three business sectors achieved organic increases in sales and earnings. Accordingly, the company remains on course to return to profitable growth in fiscal 2024, as previously announced.
“As expected, we continued our growth course in the third quarter. We confirm our guidance of profitable growth in fiscal 2024,” said Belén Garijo, Chair of the Executive Board and CEO of Merck. “The markets in which we operate continue to experience robust growth trends and our multi-industry portfolio is optimally positioned to benefit from these positive developments.”
Due to the positive business performance in all three business sectors, Merck grew its net sales to € 5,266 million in the third quarter of 2024, achieving organic growth of 3.8%. Taking negative foreign exchange effects of 2.0% into account, Group sales grew by a total of 1.8% compared with the year-earlier quarter.
EBITDA pre rose organically by 16.9%. This was driven by sales growth, strict cost discipline and the temporarily lower spend on research and development in Healthcare. Including negative foreign exchange effects of 5.0%, earnings saw double-digit growth of 11.9% to € 1,618 million overall. The EBITDA pre margin increased to 30.7% compared to 27.9% in the year-earlier quarter. Earnings per share pre amounted to € 2.30.
Source: https://www.merckgroup.com/en/news/q3-2024-14-11-2024.html
